Animal models of CNS disorders

Area of Science:

• Neuroscience
• Pharmacology
• Biomedical Research

Background:

• Animal models are vital for studying Central Nervous System (CNS) disorders, identifying biomarkers, and assessing new chemical entities (NCEs).
• Despite historical successes in discovering treatments for anxiety, depression, schizophrenia, and Parkinson's disease, recent clinical trial failures have led to criticism of these models.
• Complexities of CNS disorders, subjective endpoints, and limited mechanistic understanding pose significant challenges.

Purpose of the Study:

• To review the rationale, strengths, weaknesses, and predictive validity of common animal models for psychiatric, neurodegenerative, and neurological disorders.
• To discuss factors influencing the variability and reproducibility of these models.
• To examine the impact of molecular genetics and transgenic animals on neurodegenerative disorder research.

Main Methods:

• Literature review and critical analysis of existing animal models for CNS disorders.
• Discussion of preclinical and clinical trial outcomes.
• Exploration of advancements in genetic engineering and their application in animal models.

Main Results:

• Animal models have been instrumental in CNS drug discovery but face limitations leading to clinical trial failures.
• Transgenic animal models have advanced neurodegenerative research but have not yet been a complete solution for drug discovery.
• Model refinement and a better understanding of variability are crucial for improving predictive validity.

Conclusions:

• Animal models remain essential tools for CNS disorder research, but their limitations require careful consideration.
• Ongoing advancements, particularly in transgenic technologies, are improving the utility of animal models.
• Continued refinement and critical evaluation are necessary to enhance the translational success of preclinical findings to clinical applications.